全文获取类型
收费全文 | 67869篇 |
免费 | 4913篇 |
国内免费 | 305篇 |
专业分类
耳鼻咽喉 | 610篇 |
儿科学 | 2082篇 |
妇产科学 | 1680篇 |
基础医学 | 9835篇 |
口腔科学 | 1607篇 |
临床医学 | 6937篇 |
内科学 | 14513篇 |
皮肤病学 | 1504篇 |
神经病学 | 7452篇 |
特种医学 | 1638篇 |
外科学 | 6204篇 |
综合类 | 423篇 |
一般理论 | 68篇 |
预防医学 | 7519篇 |
眼科学 | 1067篇 |
药学 | 4464篇 |
中国医学 | 192篇 |
肿瘤学 | 5292篇 |
出版年
2023年 | 805篇 |
2022年 | 635篇 |
2021年 | 2751篇 |
2020年 | 1850篇 |
2019年 | 2531篇 |
2018年 | 2919篇 |
2017年 | 1972篇 |
2016年 | 2237篇 |
2015年 | 2449篇 |
2014年 | 3087篇 |
2013年 | 3957篇 |
2012年 | 6281篇 |
2011年 | 6335篇 |
2010年 | 3261篇 |
2009年 | 2791篇 |
2008年 | 4564篇 |
2007年 | 4465篇 |
2006年 | 4197篇 |
2005年 | 3869篇 |
2004年 | 3418篇 |
2003年 | 2994篇 |
2002年 | 2572篇 |
2001年 | 280篇 |
2000年 | 195篇 |
1999年 | 249篇 |
1998年 | 359篇 |
1997年 | 276篇 |
1996年 | 216篇 |
1995年 | 229篇 |
1994年 | 177篇 |
1993年 | 166篇 |
1992年 | 106篇 |
1991年 | 97篇 |
1990年 | 83篇 |
1989年 | 86篇 |
1988年 | 75篇 |
1987年 | 46篇 |
1986年 | 56篇 |
1985年 | 50篇 |
1984年 | 69篇 |
1983年 | 57篇 |
1982年 | 49篇 |
1981年 | 48篇 |
1980年 | 31篇 |
1979年 | 23篇 |
1978年 | 18篇 |
1977年 | 25篇 |
1976年 | 10篇 |
1975年 | 10篇 |
1973年 | 9篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
1.
Deitelzweig Steve Luo Xuemei Nguyen Jennifer L. Malhotra Deepa Emir Birol Russ Cristina Li Xiaoyan Lee Theodore C. Ferri Mauricio Wiederkehr Danny Reimbaeva Maya Barnes Geoffrey D. Piazza Gregory 《Journal of thrombosis and thrombolysis》2022,54(4):696-696
Journal of Thrombosis and Thrombolysis - 相似文献
2.
3.
Laura A. Huppert MD Ozge Gumusay MD Dame Idossa MD Hope S. Rugo MD 《CA: a cancer journal for clinicians》2023,73(5):480-515
Hormone receptor (HR)-positive and human epidermal growth factor receptor 2 (HER2)-negative breast cancer is defined by the presence of the estrogen receptor and/or the progesterone receptor and the absence of HER2 gene amplification. HR-positive/HER2-negative breast cancer accounts for 65%–70% of all breast cancers, and incidence increases with increasing age. Treatment varies by stage, and endocrine therapy is the mainstay of treatment in both early stage and late-stage disease. Combinations with cyclin-dependent kinase 4/6 inhibitors have reduced distant recurrence in the early stage setting and improved overall survival in the metastatic setting. Chemotherapy is used based on stage and tumor biology in the early stage setting and after endocrine resistance for advanced disease. New therapies, including novel endocrine agents and antibody-drug conjugates, are now changing the treatment landscape. With the availability of new treatment options, it is important to define the optimal sequence of treatment to maximize clinical benefit while minimizing toxicity. In this review, the authors first discuss the pathologic and molecular features of HR-positive/HER2-negative breast cancer and mechanisms of endocrine resistance. Then, they discuss current and emerging therapies for both early stage and metastatic HR-positive/HER2-negative breast cancer, including treatment algorithms based on current data. 相似文献
4.
Olivari Davide De Giorgio Daria Staszewsky Lidia Irene Fumagalli Francesca Boccardo Antonio Novelli Deborah Manfredi Martina Babini Giovanni Luciani Anita Ruggeri Laura Magliocca Aurora Zani Davide Danilo Masson Serge Belloli Angelo Pravettoni Davide Maiocchi Giuseppe Latini Roberto Ristagno Giuseppe 《Cardiovascular drugs and therapy / sponsored by the International Society of Cardiovascular Pharmacotherapy》2022,36(4):727-738
Cardiovascular Drugs and Therapy - Available animal models of acute heart failure (AHF) and their limitations are discussed herein. A novel and preclinically relevant porcine model of decompensated... 相似文献
5.
Bradshaw Paige Garber Keegan Shaun Foertsch Madeline Yang George L. Ngwenya Laura B. Srinivasan Vasisht 《Journal of thrombosis and thrombolysis》2022,54(2):295-300
Journal of Thrombosis and Thrombolysis - The ongoing controversy regarding optimal reversal agent for factor Xa-inhibitors is mainly due to lack of comparative data of andexanet alfa (AA) to... 相似文献
6.
Matthew C. Phillips Laura Sarff Josh Banerjee Chase Coffey Paul Holtom Steve Meurer Noah Wald-Dickler Brad Spellberg 《Journal of medical virology》2022,94(1):318-326
When hospitals first encountered coronavirus disease 2019 (COVID-19), there was a dearth of therapeutic options and nearly 1 in 3 patients died from the disease. By the summer of 2020, as deaths from the disease declined nationally, multiple single-center studies began to report declining mortality of patients with COVID-19. To evaluate the effect of COVID-19 on hospital-based mortality, we searched the Vizient Clinical Data Base for outcomes data from approximately 600 participating hospitals, including 130 academic medical centers, from January 2017 through December 2020. More than 32 million hospital admissions were included in the analysis. After an initial spike, mortality from COVID-19 declined in all regions of the country to under 10% by June 2020 and remained constant for the remainder of the year. Despite this, inpatient, all-cause mortality has increased since the beginning of the pandemic, even those without respiratory failure. Inpatient mortality has particularly increased in elderly patients and in those requiring intubation for respiratory failure. Since June 2020, COVID-19 kills one in every 10 patients admitted to the hospital with this diagnosis. The addition of this new disease has raised overall hospital mortality especially those who require intubation for respiratory failure. 相似文献
7.
Davide Fiore Bavaro Flavia Balena Luigi Ronga Fabio Signorile Federica Romanelli Stefania Stolfa Eleonora Sparapano Carmela De Carlo Adriana Mosca Laura Monno Gioacchino Angarano Annalisa Saracino 《Journal de Mycologie Médicale》2022,32(1):101206
An increased number of patients is at risk of Candida spp. bloodstream infection (CBSI) in modern medicine. Moreover, the rising of antifungal resistance (AR) was recently reported. All consecutive CBSI occurred in our Hospital (consisting of 1,370 beds) between 2015 and 2018, were reviewed. For each case, Candida species, AR pattern, ward involved and demographic data of patients were recorded. Overall, 304 episodes of CBSI occurred, with a median (q1:first-,q3:third quartile) of 77 (71-82) CBSI/year. Over the years, a significant increase of CBSI due to C. albicans compared to non-albicans strains was recorded in medical wards (from 65% to 71%, p=0.030), while this ratio remained stable in others. An increase of resistant strains to multiple antifungals such as C. guillermondii was noticed in recent years (from 0% to 9.8%, p=0.008). Additionally, from 2015 to 2018 an increase in fluconazole-resistance was recorded in our Hospital (from 7.4% to 17.4%, p=0.025) and a slight increase in voriconazole-resistance (from 0% to 7% in 2018, p=0.161) was observed, while resistance to echinocandin and amphotericin B remained firmly below 2%.This study suggests a rapid spread of antifungal resistance in our Hospital; therefore, an appropriate antifungal stewardship programs is urgently warranted. 相似文献
8.
9.
10.
Dominski Fábio Hech Serafim Thiago Teixeira Siqueira Thais Cristina Andrade Alexandro 《Sport Sciences for Health》2021,17(1):21-41
Sport Sciences for Health - This study aimed to review the existing literature concerning the psychological variables of CrossFit participants. This review followed the PRISMA guidelines and was... 相似文献